망막정맥폐쇄 환자에서 유리체내 베바시주맙 주입술의 2년 임상 결과

• 영문명: Two-Year Results of Intravitreal Bevacizumab Injection in Retinal Vein Occlusion
• 발행기관: 대한안과학회
• 저자명: 이영섭 김무상 유승영 곽형우,Young Seob Lee, MD, Moo Sang Kim, MD, Seung Young Yu, MD, Hyung Woo Kwak, MD
• 간행물 정보: 『대한안과학회지』Ophthalmological Society,volume52,number9, 1039~1047쪽, 전체 9쪽
• 주제분류: 의약학 > 의학일반
• 파일형태: PDF
• 발행일자: 2011.09.15

영문 초록

Purpose: The authors evaluated the 2-year clinical results of intravitreal bevacizumab injection in retinal vein occlusion (RVO). Methods: Thirty-two eyes of 32 patients treated with an intravitreal bevacizumab injection of 1.25 mg (0.05 ml) for RVO (branch RVO: 22 eyes, central RVO: 10 eyes), repeated 3 times at a 6-week interval and were available for a follow-up period of at least 2 years were retrospectively reviewed. Best-corrected visual acuity (BCVA) before treatment and 6, 12, and 24 months after 3 serial injections, was recorded. The optical coherence tomography (OCT) results were analyzed to identify prognostic factors for recurrent macular edema that needed reinjection. Results: Two years after the treatment, mean BCVA was significantly improved (p = 0.000). Out of 32 eyes, 16 (branch RVO: 8 eyes; central RVO: 8 eyes) needed reinjection because of recurrent macular edema. In central RVO, a significantly high reinjection rate was shown in serous retinal detachment (SRD) compared with cystoid macular edema (CME) as identified in OCT findings (p = 0.049). Additionally, in branch RVO, a high reinjection rate was shown in SRD, although statistically not significant (p = 0.375). Conclusions: In patients with RVO, a significant visual improvement was maintained for at least 2 years after intravitreal bevacizumab injection. Based on OCT results, SRD showed a high reinjection rate compared with CME in CRVO. J Korean Ophthalmol Soc 2011;52(9):1039-1047

키워드

Bevacizumab, Macular edema, OCT results, Retinal vein occlusion, Two-year results